AP20 Rec'd PCT/PTQ 26 JUL 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Alain MOUSSY et al.

Title:

2-(3-SUBSTITUTED-ARYL) AMINO-4-

ARYL-THIAZOLES AS TYROSINE KINASE

INHIBITORS

Appl. No.:

Unassigned

International

1/28/2005

Filing Date: 371(c) Date:

Examiner:

Unassigned

Art Unit:

Unassigned

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the date of entry of the national stage as set forth in 37 CFR §1.491.

RELEVANCE OF EACH DOCUMENT

The documents being cited in the attached PTO/SB/08 were cited as being relevant during the prosecution of the corresponding international application. A copy of the International Search Report is attached setting forth the portion of the documents considered relevant by the examiner. Copies of the cited references listed in the Search Report are not being submitted herewith.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

-2-

Respectfully submitted

Stephen B. Maebius

Attorney for Applicant

Registration No. 35,264

Date July 26, 2006

FOLEY & LARDNER LLP

Customer Number: 22428

Telephone: (202) 672-5569

Facsimile: (202) 672-5399

AP20 Rec'd PCT/PTO 2 6 JULY 2006/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for form 1449B/PTO					Complete if Known		
	11	NFORMATION DIS	3CLO	SURE		Application Number	Unassigned U./ 20/ 420	
	S	TATEMENT BY A	\PPLI	CANT	ĺ	Filing Date	1/28/2005	
Data Submitted: July 26, 2006						First Named Inventor	Alain Moussy	
Date Submitted: July 26, 2006						Group Art Unit	Unassigned	
	(use	e as many sheets	as ne	cessary)		Examiner Name	Unassigned	
Sheet		1	of	1		Attorney Docket Number	065691-0457	

	U.S. PATENT DOCUMENTS							
Examiner Initials*		U.S. Patent	Document	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	Cite No. ¹	Number	Kind Code ² (if known)					
	-							

				F	DREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No.1	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	A1	wo	03/004467	Α	Agouron Pharmaceuticals, Inc.	01/16/2003		
	A2	WO	03/062215	Α	Kylix Pharmaceuticals B.V.	07/31/2003		
	A3	wo	2004/014903	Α	AB Science	02/19/2004		
	A4	wo	2005/000298	Α	Triad Therapeutics, Inc.	01/06/2005		-

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				
	A5	Database Bielstein Beilstein Institute for Organic Chemistry, XP002328977, Database accession no. BRN: 260633 abstract & Yakugaku Zasshi, vol. 75, 1955, p. 1082.				
	A6	Database Bielstein Beilstein Institute for Organic Chemistry, XP002328978, Database accession no. BRN: 7227176 abstract & J. Indian Chem. Soc., vol. 71, no. 4, 1994, pp. 205-208.				
	A7	Database Bielstein Beilstein Institute for Organic Chemistry, XP002328979, Database accession no. BRN: 5076163 abstract & Indian J. Chem. Sect. B, vol. 26, no. 1-12, 1987, pp. 856-860.				
	A8	Database Bielstein Beilstein Institute for Organic Chemistry, XP002328980, Database accession no. BRN: 3761233 abstract & Yakugaku Zasshi, vol. 75, 1955, p. 1077.				

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.